FENC: fennecpharma.com Amount of Cash per Share

Fennec Pharmaceuticals (FENC) management is effectively optimizing Pedmark distribution while maintaining high operating margins. The business occupies a niche hearing protection segment where changes in treatment protocols remain the primary risk. The trend in cash cushion per share demonstrates that the metric remains around 1.39. A steady cash inflow is ensured by its status as the sole commercial product for children, creating a solid financial foundation.
Analytical breakdowns for Fennec Pharmaceuticals

This metric is calculated as the ratio of available liquidity to the number of shares outstanding, determining the cash reserve per share to assess financial stability. By analyzing the cash position per share, an investor can identify the risks associated with Fennec Pharmaceuticals (FENC), where a critical dependence on a single niche drug makes the cash reserve the sole guarantor of survival amid limited business scaling.